To estimate the prostate cancer risk conferred by individual single nucleotide polymorphisms (SNPs), SNP-SNP interactions, and/or cumulative SNP effects, we evaluated the association between prostate cancer risk and the genetic variants of 12 key genes within the steroid hormone pathway (CYP17, HSD17B3, ESR1, SRD5A2, HSD3B1, HSD3B2, CYP19, CYP1A1, CYP1B1, CYP3A4, CYP27B1, and CYP24A1). A total of 116 tagged SNPs covering the group of genes were analyzed in 2,452 samples (886 cases and 1,566 controls) in three ethnic/ racial groups. Several SNPs within CYP19 were significantly associated with prostate cancer in all three ethnicities (P = 0.001-0.009). Genetic variants within HSD3B2 and CYP24A1 conferred increased risk of prostate cancer in non-Hispanic or Hispanic Caucasians. A significant gene-dosage effect for increasing numbers of potential high-risk genotypes was found in non-Hispanic and Hispanic Caucasians. Higher-order interactions showed a seven-SNP interaction involving HSD17B3, CYP19, and CYP24A1 in Hispanic Caucasians (P = 0.001). In African Americans, a 10-locus model, with SNPs located within SRD5A2, HSD17B3, CYP17, CYP27B1, CYP19 , and CYP24A1, showed a significant interaction (P = 0.014). In non-Hispanic Caucasians, an interaction of four SNPs in HSD3B2, HSD17B3, and CYP19 was found (P < 0.001). These data are consistent with a polygenic model of prostate cancer, indicating that multiple interacting genes of the steroid hormone pathway confer increased risk of prostate cancer.
Introduction
The underlying etiology of prostate cancer is poorly understood, with genetic predisposition and environmental factors likely contributing to risk (1) . Heritable risk factors can involve highly penetrant susceptibility genes with low frequencies and/or low-penetrant genes with higher frequencies in the population. The majority of prostate cancer cases likely involve more common, low-penetrant to moderate-penetrant alleles in genes that are components of functional prostatic pathways, such as androgen hormones and their metabolizing enzymes (2) (3) (4) .
Evidence exists that the steroid hormone pathway and genes involved in the metabolism of estrogens and androgens affect the risk of prostate cancer (4) . Androgens are essential for the development, growth, and secretory activities of the prostate, whereas estrogens modulate these effects. Several of the cytochrome p450 enzymes participate in the synthesis of testosterone from cholesterol (ref. 5 ; Fig. 1 ). The CYP17 gene (10q24.3, MIM 609300) encodes steroid 17a-hydroxylase and is a member of the cytochrome P450 super family. CYP17 mediates both 17a-hydroxylase and 17,20-lyase activity, and is involved in the biosynthesis of both 17a-hydroxylated glucocorticoids and sex steroids (6) (7) (8) . The final step in the synthesis of testosterone is the conversion of androstenedione to testosterone by 17h-hydroxysteroid dehydrogenase type 3 (HSD17B3, 9q22, MIM 605573). Testosterone, along with estrone and estradiol, interact with the estrogen receptor ESR1 (6q25.1, MIM 133430), leading to the activation of the enzyme steroid 5a-reductase type 2 (SRD5A2, 2p23, MIM 607306). Testosterone is irreversibly metabolized to dihydrotestosterone by SRD5A2 . Normal prostate growth and development requires dihydrotestosterone and a functioning of SRD5A2 (4). Dihydrotestosterone stimulates the transcription of several genes with androgen-responsive elements in their promoters and is inactivated in the prostate by hydroxy-y5-steroid dehydrogenase, 3h and steroid y-isomerase 1 (HSD3B1, 1p13.1, MIM 109715), hydroxy-y5-steroid dehydrogenase, and 3h and steroid y-isomerase 2 (HSD3B2, 1p13.1, MIM 201810). In the prostate, androstenedione and testosterone can also be converted by aromatase (cytochrome p450, family 19, subfamily A, polypeptide 1; CYP19, 15q21.1, MIM 107910) into estrone and estradiol, which are then metabolized by genes from the cytochrome P450 family, including CYP1A1 (15q22-q24, MIM 108330), CYP1B1 (2p21, MIM 601771), and CYP3A4 (7q21.1, MIM 124010) into hydroxy and methoxy estrogens (Fig. 1) .
The growth and differentiation of normal prostatic tissue is also promoted by interactions between the vitamin D and dihydrotestosterone pathways (9) . Levels of the bioactive form of vitamin D are controlled by both the activating enzyme 1-A-hydroxylase (CYP27B1 , 12q13.1-q13.3, MIM 609506) and the deactivating enzyme 24-hyroxylase (CYP24A1, 20q13, MIM 126065), which regulate cell growth and may reduce the risk of malignant transformation.
Functional variants in the genes of these pathways are likely to influence prostate carcinogenesis. Significant associations between variants in one or more of the above genes and risk for prostate cancer have been reported but with inconsistent findings. For example, meta-analyses of single nucleotide polymorphisms (SNPs) within CYP17, including rs743572, or SNPs rs523349 (V89L) and rs9282858 (A49T) within SRD5A2 did not support evidence for association with risk of prostate cancer although smaller studies reported on significant risk effects (10) (11) (12) . Recent efforts evaluating these risk variants relied on single-gene approaches. With a multicausal etiology of prostate cancer, it is likely that multiple risk variants act simultaneously, synergistically, or additively to influence prostate cancer susceptibility. Additionally, in most studies only a small proportion of the estimated number of genetic variants was analyzed, and the contributions of variants in regulatory, noncoding regions of genes, rather than in exons, were often omitted and probably underestimated because transcriptional regulatory elements are located in introns.
We systematically evaluated the association of genetic variants of 12 key genes within the steroid hormone pathway and prostate cancer risk, including CYP17, HSD17B3, ESR1, SRD5A2, HSD3B1, HSD3B2, CYP19, CYP1A1, CYP1B1, CYP3A4, CYP27B1, and CYP24A1, and genotyped 116 tagged SNPs covering the genes in 2,452 samples (886 cases and 1,566 controls) of nonHispanic Caucasian, Hispanic Caucasian, or African American origin. We report on the association of individual SNPs as well as higher-order SNP-SNP interactions. We also tested the hypothesis that individuals carrying multiple copies of risk variants are at increased risk for prostate cancer.
Materials and Methods
Subjects. Study subjects included men from the San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort. The San Antonio Center for Biomarkers of Risk of Prostate Cancer is funded by the National Cancer Institute and has been prospectively enrolling healthy male volunteers since 2001. On each annual visit, a digital rectal examination was done and the serum prostate-specific antigen level was determined. From this cohort, 231 incident cases (135 non-Hispanic Caucasians, 60 Hispanic Caucasians, and 36 African Americans) were available. We also included 655 cases with a known Figure 1 . Summary of the steroid hormone pathway indicating the candidate genes studied in this report and the products from their enzymatic reactions.
history of prostate cancer that are enrolled within the same time period in a parallel study of prevalent prostate cancer. These prevalent cases were recruited through the same means and from the same metropolitan population as the San Antonio Center for Biomarkers of Risk of Prostate Cancer study and had a median time period of 3 y (range, 0-25 y) between disease diagnosis and enrollment into the study. Cases had biopsy-confirmed prostate cancer, and controls consisted of male volunteers at least 45 y old who had normal digital rectal examinations and prostate-specific antigen levels <2.5 ng/mL on all study visits. Race/ethnicity was self-reported on a questionnaire filled out at a clinic site at the time of recruiting, and the Hazuda algorithm (13) was used to classify race/ethnicity. All participants have established U.S. residency and are believed to be long-term residents. Study age among controls was the age at last follow-up, and age among cases was the age at prostate cancer diagnosis. Our control group was younger than our prostate cancer cases, with a mean age (SD) of 60. 8 (8.8) y for the controls and a mean age (SD) of 65.5 (8.5) y for the cases (P < 0.0001). The clinical characteristics of the subjects are summarized in Table 1 SNP Selection and Genotyping. DNA was isolated from participants' whole blood cells with the use of a QIAamp DNA Blood Maxi Kit (Qiagen).
A total of 120 SNPs within the 12 candidate genes were selected based on the following criteria. We first selected SNPs from available databases, the National Center for Biotechnology Information (http://www.ncbi.nlm.nih. gov/projects/SNP/) and SNPper (http://snpper.chip. org/), using the following criteria: (a) Within each gene, SNPs with a minor allele frequency >0.05, which leads to an amino acid substitution, and/or are in other coding regions of the gene and thus potentially functionally important were selected, (b) SNPs for which an association with prostate cancer has previously been shown as reported in literature were chosen. After this initial selection, we identified tagging SNPs within each gene using Haploview with the following criteria: (a) a minor allele frequency >0.05 to gain more statistical power, (b) an r 2 threshold of 0.8 and a log of odds threshold for multimarker testing of 3.0, (c) a minimum distance between tags of 60 bp, (d) we included our preselected SNPs (see above), (e) for each gene the search for SNPs extended to a 10 kb region surrounding the gene, and (f) we used the 2-marker and 3-marker haplotype tagging option (http://www.broad.mit.edu/ mpg/haploview/). The selection was based on information on the European population as provided by HapMap (www.hapmap.org). The SNPs are described in Table 2 .
Genotyping of 104 of the 120 SNPs was done with the GoldenGate assay of the VeraCode technology with the use of the BeadXpress Reader System according to the manufacturer's protocol (Illumina). SNPs rs2066479 (HSD17B3), rs1048943 (CYP1A1), rs2740574 (CYP3A4), and rs700519 (CYP19) were done with a standard TaqMan allelic discrimination assay with the use of an ABI 7900HT Sequence Detection System with the SDS 2.1 software (Applied Biosystems). Genotyping of the seven SNPs within CYP1B1 was as previously described (14 SNPs in the controls and cases of each race/ethnicity (ref. 18 ; http://www.broad.mit.edu/mpg/haploview/). The allele frequency for each SNP was determined in each ethnic group, and the frequencies among the casecontrol groups were compared with the use of the m 2 test. Association analyses were stratified by ethnicity and done with the R statistical software version 2.5.1. The odds ratio (OR) and its 95% confidence interval (CI) were estimated by unconditional logistic regression as a measure of the associations between genotypes and prostate cancer risk. We tested for additive, dominant, and recessive associations. To correct for multiple testing, we used the method of Storey and Tibshirani (2003) based on the concept of false discovery rate (19) . This estimation showed that, for P < 0.01, the probability that the association is expected to be a true positive in our importance of the polymorphisms and potential nonlinear interactions with respect to the outcome variable (20) . For each RF analysis, the number of trees to grow (''ntree'') was set to 5,000, and the number of predictors to be randomly selected at each tree node (''mtry'') was set to 20. To better characterize and validate the ''important'' polymorphisms identified by both the RF algorithm as well as single SNP analysis, and to determine possible interactions between the top ranked or significant SNPs within the same or different genes, we used the generalized multifactor dimensionality reduction (GMDR) method (ref. 21 ; The GMDR P values and other significance tests are representative of consistency with RF but do not indicate independent confirmation of RF findings). An exhaustive search of all possible n models was done for subsets of selected SNPs (with n between 1 and 10). We used 10-fold crossvalidations for each set of n SNPs, and the model with the lowest misclassification error was selected. P values were determined by the sign test, a robust nonparametric test implemented in the software. We also calculated empirical P values for interaction based on 1,000 permutations. Missing values were imputed for both the RF and GMDR methods. The RF method imputes missing data by computing a weighted average of subjects with completed data, in which the weights are similarity measures to the subjects with missing data. The MDR data tool was used to impute missing values in the GMDR analysis (http://sourceforge.net/project/showfiles.php? group_id=131001&package_id=144548). The cumulative effect of combined genotypes on prostate cancer risk was estimated by counting the number of genotypes associated with prostate cancer on the basis of the best-fitting genetic inheritance from single SNP analysis. ORs and their 95% CIs were calculated for men carrying any combination of one, two, or more alleles associated with prostate cancer compared with men carrying none of the risk genotypes with the use of unconditional logistic regression analysis. We selected SNPs that were not in linkage disequilibrium with each other (D' < 0.8). If several SNPs presented higher linkage disequilibrium values, we chose a SNP in a coding region above an intronic SNP and also selected the most significant SNP.
For all statistical analyses, age (modeled as a continuous predictor) was used as covariate. Individuals with missing data for a particular analysis were removed from the analysis. All statistical tests were two-sided, and significance was set at P < 0.05.
A hypothetical function for SNPs that were significant for single SNP analysis and/or selected by RF was assessed with the use of in silico analysis of transcription factor binding sites: both possible alleles of each SNP were tested for their binding capability to human transcription factors with the use of the web tool 'transcription element search system' (TESS; ref. 22 ; http://www.cbil.upenn.edu/cgi-bin/tess/tess). The options used were 21 bases of genomic sequence around each SNP (10 bases on either side of the SNP) and a string-based search query with default settings. A log-likelihood score of >16 for a pretty good match (deficit V1.0) and >18 for a mismatch (deficit >1.0) were used as cut-off values for reporting.
Results
Single SNP Analysis. A total of 120 SNPs were genotyped in 2,452 samples. The majority of SNPs (>80%) were successfully genotyped in >90% of the samples. Three SNPs failed, and one SNP was not polymorphic in our sample. Table 2 gives the minor allele frequencies of the SNPs estimated in each of the three ethnicities in our study sample. Differences in allele frequency distribution among the ethnicities were found for several SNPs (e.g., rs4646450 in CYP3A4 shows a minor allele frequency of f15% for the A allele in non-Hispanic Caucasians, of f30% in Hispanic Caucasians, and of f85% in African Americans). Significant case/control differences of allele frequencies at a level <0.05 were observed for eight polymorphisms in non-Hispanic Caucasians, for seven SNPs within Hispanic Caucasians, and for five SNPs in African Americans (Table 2) . One SNP, rs6201, showed deviation from Hardy-Weinberg equilibrium (P < 0.01) in the cases and controls of all three ethnic study groups. In non-Hispanic and Hispanic Caucasians, rs10923823 was also not in Hardy-Weinberg equilibrium in the cases nor the controls, and variant rs3751592 was out of Hardy-Weinberg equilibrium in non-Hispanic Caucasians. Although the error rate was <0.2%, SNPs that were not in Hardy-Weinberg equilibrium were left out for further statistical analyses in the respective study groups.
Logistic regression analysis was done for all SNPs in the context of recessive, dominant, and additive models after adjustment for age. Thirteen SNPs in four genes were significantly associated with prostate cancer risk in non-Hispanic Caucasians at the P < 0.05 level. For Hispanic Caucasians, 19 SNPs in six genes were found to be significant for prostate cancer risk, and in African Tables S1, S2 , and S3. After correction for multiple testing, estimating a false discovery rate of <50% for P < 0.01, five SNPs remained significant in non-Hispanic Caucasians, rs1819698 and rs1538989 within HSD3B2, rs12439137, and rs2470152 and rs2470164 within CYP19 (P = 0.001-0.008; Table 3 ). There was a moderate increase (f1.5) or decrease (f0.6) in the ORs associated with these significant results. In Hispanic Caucasians, four SNPs remained significant after correction for multiple testing (P = 0.003-0.009), three SNPs within CYP19 (rs934632, rs10519295, and rs10459592) and one SNP within CYP24A11 (rs3787554). The P values were associated with a >2-fold increase or decrease in OR (Table 3) . In African Americans, the association with prostate cancer risk remained significant for rs3751592 in CYP19, with P = 0.008 and a >2.5 increase in OR for the AG heterozygote carriers. In all three sample groups, one or multiple single SNPs within CYP19 showed significant association with prostate cancer. Except for rs1819698 (CYP19), located within the 3 ¶ untranslated region of the gene, all other significant SNPs are within intronic regions of the genes. We also tested whether the statistically significant associations with prostate cancer represented independent risk factors in our sample groups. In the non-Hispanic Caucasians, rs2470164 remained significant after correction for the other four significant SNPs (P = 0.0007) under the additive model. SNP rs3787554 in the Hispanic Caucasians remained significant after adjusting for the other significant SNPs (P = 0.004; data not shown). In African Americans, only one SNP remained significant after correction for multiple testing.
Cumulative Effect of Significant SNPs. To evaluate possible cumulative effects of the risk alleles defined in the single SNP analysis, we did an age-adjusted multivariate logistic regression on combinations of atrisk alleles compared with the no-risk allele reference. In non-Hispanic Caucasians, the combination of the three risk alleles not in linkage disequilibrium with each other showed a significant association with prostate cancer (P trend = 2.9 Â 10 -4 ), and a >2-fold increase in risk (OR, 2.20; 95% CI, 1.44-3.38) was observed for individuals carrying all three risk alleles compared with individuals without any risk allele (Table 4) . A similar observation was found in the Hispanic Caucasians, in which the significant association between the combination of the risk alleles of two SNPs and prostate cancer increases the risk significantly (OR, 4.29; 95% CI, 2.11-8.72; P trend = 6.4 Â 10 -5 ). In African Americans, there was only one SNP that remained significant after correction for multiple testing.
RF Analysis. To classify and predict the underlying relationships between the predictor variables and prostate cancer, we assessed the importance of the polymorphisms studied in this report by running the RF algorithm. For non-Hispanic Caucasians, Hispanic Caucasians, and African Americans, the number of SNPs chosen were 92, 91, and 97, respectively, corresponding to the missing genotypes in each sample group. Supplementary Table S4 (b) shows the top-12 ranked SNPs as calculated by RF in each of the three sample groups (a choice of 12 SNPs is arbitrary albeit motivated by reasoning that we investigated 12 genes in this report). Of the 5 significant SNPs from single SNP analysis in non-Hispanic Caucasians, 2 are ranked within the first 12 SNPs by RF. In Hispanic Caucasians, 2 of the significant SNPs were selected in the 12 most important SNPs. In African Americans, only 1 of the 3 significant SNPs was scored by RF within the 12 most important SNPs. One SNP, rs11636639 (CYP19), was common in the selection by RF in all three race/ethnic groups. SNP rs2470152 (CYP19) was present in the top-12 list of both non-Hispanic and Hispanic Caucasians. Two SNPs, rs10519295 (CYP19) and rs8176345 (CYP27B1), were within the top 12 SNPs for Hispanic Caucasians and African Americans. Although several of the SNPs selected by RF are coding SNPs, no nonsynonymous SNPs were selected.
SNP-SNP Interaction. The RF algorithm is aimed at detecting the variables that have an important role in the prediction of the outcome, but it does not indicate how these predictors act (i.e., through main effects or through interactive effects involving other variables). Furthermore, because the genes studied are all found in one pathway, possible interactions between single SNPs might exist. SNP-SNP interaction was determined with the use of GMDR. For each racial/ethnicity group, we looked at possible interactions between the significant SNPs found in the single SNP analysis before multiple correction as well as the top-12 ranked SNPs from RF. A summary of the significant results for the models that have minimum prediction error (maximum testing accuracy) and/or maximum cross-validation consistency (CVC) is presented in Table 5 . Considering SNPs that are significant for single SNP analysis before multiple correction (see Supplementary  Tables S1, S2 , and S3), we found a significant interaction between SNPs rs1538989, rs2479827, rs17523880, and rs2470164 within HSD3B2, HSD17B3, and CYP19 in the non-Hispanic Caucasians (permutation P < 0.001; CVC, 10/10; testing accuracy, 0.63), suggesting that the four SNPs not only have a main effect, some of which are marginal, but also show a joint action of the three genes. In Hispanic Caucasians, a seven-locus model for rs523349, rs1810711, rs2066474, rs4646, rs10459592, rs2470152, and rs2762941, involving genes SRD5A2, HSB17B3, CYP19, and CYP24A1, showed a significant interaction (permutation P = 0.005; CVC, 10/10; testing accuracy, 0.60). A marginal significant interaction between five SNPs, rs10012, rs17115144, rs1048691, rs11636639, and rs3751592, within the genes CYP1B1, CYP17, CYP27B1, and CYP19 is found in African Americans (permutation P = 0.04; CVC, 10/10; testing accuracy, 0.60), indicating that those SNPs act jointly to confer prostate cancer risk.
Considering the 12 top-ranked SNPs by RF in nonHispanic Caucasians, no significant interactions were found (data not shown). In Hispanic Caucasians, a highly significant interaction (permutation P = 0.001) was found for 7 of the top-12 ranked SNPs with a CVC of 10/10 and a testing accuracy of 0.61. In African Americans, the model with the highest CVC and maximum testing accuracy included 10 of the 12 top-ranked SNPs (permutation P = 0.014; CVC, 8/10; testing accuracy, 0.63).
Alterations of Binding Sites for Transcription Factors.
To investigate possible functional implications of the significant SNPs as well as the SNPs identified by RF, a search for transcription factor binding sites with the use of the transcription element search system was done. The motive behind the analysis is that recent findings show that transcription factor binding sites may be commonly located in introns or other noncoding regions of the genome (23) . Three of the five SNPs, rs1538989, rs2470152, and rs2470164, that show significant association with prostate cancer in non-Hispanic Caucasians; one significant SNP, rs3787554, in Hispanics; and the significant SNP rs3751592 in African Americans have changes in transcription factor binding properties related to allelic alterations (Supplementary Table S4 , a). The presence of the C allele in rs1538989 (HSD3B2) creates a binding site for a transcriptional activator, PU.1. The Maz binding site, which is a transcriptional activator, is present for the T allele in rs2470152 (CYP19). A binding site for nuclear factor nB, activated by the tumor necrosis factor gene and also a transcriptional repressor of the H-2Kb gene in metastatic tumor cells, is present for the G allele in rs2470164 (CYP19). SNP rs3787554 (CYP24A1) has an Sp1 binding site for the G allele. The A allele of rs3751592 (CYP19) has a binding site for a transcriptional modulator of tumor necrosis factor-a. Table 5 . Best multigenic models, testing accuracies, cross-validation consistencies, and Considering the SNPs that were prioritized by RF, 4 of the 12 SNPs (rs4809957, rs1538989, rs2470152, and rs703842) were found to display a binding difference of transcription factors in an allele-specific manner in non-Hispanic Caucasians; 4 of the 12 SNPs (rs11636686, rs10989735, rs1810711, and rs2470152) affect a binding site for transcription factors in Hispanic Caucasians; and 2 SNPs (rs2414099 and rs2208532) show allele-specific alterations of binding motives in African Americans (Supplementary Table S4, b) . Of particular interest is the finding for rs4809957 (CYP24A1) in non-Hispanic Caucasians, for which the A allele creates a binding site for the retinoic acid -responsive element. In Hispanic Caucasians, 1 SNP is noteworthy: rs10989735 (HSD17B3), in which the G allele contains an Sp1 transcription factor binding site. In African Americans, the G allele at rs2208532 (SRD5A2) has a LEF1 binding site, which induces neoplastic transformation.
Discussion
Prostate carcinogenesis is a multistep process involving a multifactorial interplay between genetic and environmental factors; as a result, the effect of individual SNPs are unlikely to be substantial and may be of limited value in predicting risk. A comprehensive approach is required, such as the pathway-based multigenic method integrating multiple polymorphisms that interact in the same pathway. Combining multiple low-penetrant to modestly penetrant SNPs may amplify predictive power.
To estimate prostate cancer risk conferred by individual SNPs, SNP-SNP interactions, and/or cumulative SNP effects, we selected 12 key genes of the steroid hormone pathway and report on the contribution of 116 SNPs within those genes to prostate cancer susceptibility. A total of 886 cases and 1,566 healthy controls from three racial/ ethnic groups of the San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort were genotyped.
When analyzed individually, a limited number of SNPs conferred increased risk of prostate cancer after correction for multiple testing (five in non-Hispanic Caucasians, four in Hispanic Caucasians, and three in African Americans). SNPs within CYP19 were significantly associated with prostate cancer in all three ethnic groups, indicating that this gene likely plays a consistent role in prostate cancer susceptibility. CYP19 is a key enzyme in the conversion of androstenedione and testosterone into estrone and estradiol, and a lack of normal function could affect testosterone concentrations, in turn influencing risk of prostate cancer (24, 25) . Furthermore, rs2470164 (CYP19) is significant in both non-Hispanic Caucasians and African Americans. Importantly, the allele frequency distribution is significantly different between the two ethnicities with C as the major allele in non-Hispanic Caucasians, whereas this allele is the rare allele in African Americans, and the effect of the SNP differs between both races; male homozygotes of the AA allele have a decreased risk in non-Hispanic Caucasians, whereas heterozygote AC increases risk in African Americans. The SNP rs2470164 has not been reported in previous association studies with prostate cancer.
Of the SNPs analyzed in this report, 35 (f30%) have been previously studied in prostate cancer. Only two of the significant SNPs from single SNP analysis (rs1819698 in HSD3B2 and rs2470152 in CYP19, both significant in non-Hispanic Caucasians) have been previously reported and showed no association with prostate cancer in nonHispanic Whites (26, 27) . Our findings for SNPs within SRD5A2 are consistent with a previous meta-analysis that did not find evidence for a significant main effect of rs523349 (V89L) or rs9282858 (A49T; ref. 12). However, our results suggest the involvement of SRD5A2 in a polygenic model for prostate cancer risk; in particular, rs523349 and rs2208532 are part of a multilocus model that shows significant interaction in Hispanic Caucasians and African Americans, respectively. We also confirmed previous findings from a meta-analysis by Ntais et al. (10) and Setawian et al. (11) Higher-order SNP-SNP and/or gene-gene interactions among the reported genetic variants indicate that the combined effect of the polymorphisms with or without significant main effects confer risk for prostate cancer. For each race/ethnicity, significant interactions were found between SNPs with main effects (some marginal) for single SNP analysis. These results suggest interactions among HSD3B2, HSD17B3, and CYP19 in nonHispanic Caucasians; among SRD5A2, HSB17B3, CYP19, and CYP24A1 in Hispanic Caucasians; and among HSD3B2, CYP1B1, CYP17, CYP27B1, and CYP19 in African Americans. Interactions between SNPs selected by RF, several without a main effect, confirm that complex polygenic models are related to prostate cancer risk. These findings show the importance of SNPs that may not have significance at the individual level and which may be overlooked without an interaction analysis. It should be mentioned that the testing accuracies calculated by GMDR, between 60% and 63%, represent an improvement over the rate of 50% expected under random prediction and shows the importance of multigenic models.
Caution should be used when interpreting these results, especially about the biological significance of these multilocus epistatic models. The statistical modeling of interactions may also not correspond to a true biological interaction (38, 39) . However, based on the transcription element search system web tool, hypotheses related to molecular mechanisms resulting in differential activity of genes can be speculated. Several SNPs found to be important in this study, either from single SNP analysis or selected by RF method, have an allele-specific change in transcriptional binding sites and could contribute to transcriptional regulation of oncogenes, as in the case of rs2208532 (SRD5A2), or tumor necrosis factors, as in the case of rs2470164 (CYP19) or rs3751592 (CYP19). Further studies may identify the effect of these allele-specific changes and their contribution to prostate carcinogenesis.
Our results indicate a significant synergistic effect for increasing numbers of potential high-risk genotypes in both non-Hispanic and Hispanic Caucasians. Similar findings for a cumulative effect, in which commonly occurring SNPs incrementally contribute to prostate cancer risk, have been shown for genes from the steroid hormone pathway (30, 40) .
The GMDR method has many advantages over others, such as the ability to adjust for covariates and applicability to population-based study designs, including unbalanced case-control samples. In addition, GMDR does not rely on binary splits but does a systematic search through all possible genotype combinations of the SNP variables and may reveal more interactions than methods based on, for example, classification and regression trees.
A limitation of the study is that race/ethnicity is selfreported and, as in any association study, population stratification might lead to confounding results. However, misclassifications are equally likely in cases and controls, and should not have a substantial impact on the outcome. In addition, the majority of markers were not significant, suggesting that population stratification does not represent a significant problem. Another limitation is that we only evaluated the trait prostate cancer using the covariate age. Other endophenotypes and/or interactions with nongenetic factors, as well as the risk factor family history may be essential and could be related to the risk of prostate cancer, which may be missed in this study. For this report, we selected 12 key genes from the steroid hormone pathway. Because the exact mechanism by which these genes might act in prostate cancer development and progression is largely unknown, the genes investigated may represent only a fraction of all relevant genes. Moreover, the SNPs selected in the study are not an exhaustive list of all existing common SNPs and may not fully represent the genetic variability of these genes. However, a careful selection of genes and SNPs was made based on previous functional analysis and/or a previous association study related to prostate cancer risk and, thus, high-priority genes and SNPs were included in the analysis.
In summary, our results support the hypothesis that prostate cancer develops through a variety of interconnected genes, some of which belong to the steroid hormone pathway, and that there are synergistic interactions among these SNPs related to increasing prostate cancer risk. This finding is consistent with the polygenic model for cancer susceptibility, in which the combined effect of variants in many genes, each conferring a small or modest increase in risk, together account for a substantial fraction of the risk for prostate cancer. Our approach of evaluating a large number of genetic variants in a large sample size is one of the first efforts in exploring the effect of high-order gene-gene interactions on prostate cancer risk and might help in improving the ability and accuracy in assessing individual risk of prostate cancer.
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